News & Analysis on Clinical Trial Services & Contract Research And Development
Following last year's contaminated glycerin poisonings in Panama and last month's FDA guidance, US-PharmaTechnologist.com takes a look at the implications of testing for the excipient glycerin in the pharmaceutical supply chain.
Nicholas Piramal India (NPIL) has opened its second clinical research facility and is eyeing the growing area of biopharmaceutical testing.
ThalesNano Nanotechnology has launched a new version of its H-Cube flow reactor for use in higher education laboratories - the H-Cube Tutor.
In a round-up of motley pharmaceutical services contracts, Outsourcing-Pharma takes a look at recent news involving Movianto, PDI, inVentiv Health and Exel.
LabTechnologist.com brings you an exclusive interview with Chris van Ingen - the president of Agilent's Life Science and Chemical Analysis (LSCA) division.
GlaxoSmithKline's (GSK) new drug to treat a rare form of bleeding disorder has shown good results in trials so far, but while experts remain mystified as to why it works, a true cure will remain elusive.
LabTechnologist.com brings you a round up of some of the latest product releases with new offerings from Agilent, Applied Biosystems, ESA Biosciences, Illumina, Mettler-Toledo and Syrris.
Several major manufacturers have pledged millions of doses of H5N1 vaccine to go towards a global stockpiling scheme initiated by the World Health Organization to protect against the threat of an avian flu pandemic.
Just over a week after Roche was forced to initiate a Europe-wide recall of HIV drug Viracept (nelfinavir), in-PharmaTechnologist.com considers the contamination case and the pharmaceutical processes blamed for the incident.
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.
An immigration raid this week on a Fresh Del Monte Produce processing plant indicates that federal officials are continuing their campaign to crack down on the industry's use of illegal labour.
US pulmonary drug delivery specialist Respirics has decided to sell its assets relating to its MD Turbo product to focus on its Acu-Breathe powder inhaler platform.